Btk Antibody, anti-human, REAfinity™
Synonyms: AGMX1, AT, ATK, BPK, IMD1, PSCTK1, XLA
RECOMBINANT EXTENDED VALIDATION
Clone:
REA367 | 53/BTK
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for Btk Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
PE
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-128-896, 130-128-828
Description:
Human peripheral blood mononuclear cells (PBMCs) were stained with CD19 antibodies and fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-Btk antibodies or with the corresponding REA Control (I) antibodies (left images) and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application imageView details view details

Application imageView details view details
Extended validation for Btk Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA367
53-BTK
high
A16064A
low

Cells were incubated with an excess of purified unconjugated Btk (REA367) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Specifications for Btk Antibody, anti-human, REAfinity™
Overview

Clone REA367 recognizes the human bruton tyrosine kinase (Btk) antigen, a non-receptor tyrosine kinase belonging to the Tec family of kinases. Btk is critical for B cell–development, –differentiation, and –signaling. Moreover, Btk expression is assumed to be a prerequisite for B cell–proliferation and –survival. Consequently, Btk-deficient B lymphocytes fail to reach the mature state and are presumably doomed to premature death. Btk is reported to be associated with human disease. Thus, individuals harboring loss-of-function mutations in the gene encoding Btk virtually lack circulating B lymphocytes, are unable to generate immunoglobulins of all classes, and therefore cannot mount humoral immune responses. This primary immunodeficiency is named X-linked agammaglobulinemia.

Additional information: Clone REA367 displays negligible binding to Fc receptors.

Alternative names

AGMX1, AT, ATK, BPK, IMD1, PSCTK1, XLA

Detailed product information

Technical specifications

Clone
REA367
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
Btk
Molecular mass of antigen [kDa]
76
Distribution of antigen
B cells
Entrez Gene ID
RRID
AB_2727649, AB_2928184, AB_2928185, AB_2727590

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for Btk Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for Btk Antibody, anti-human, REAfinity™
Publications
  1. Mohamed, A. J. et al. (2009) Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol. Rev. 228 (1): 58-73
  2. Vetrie, D. et al. (1993) The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361 (6409): 226-233
  3. Tsukada, S. et al. (1993) Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72 (2): 279-290